Related Experiment Video

Updated: Feb 24, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K

Abiraterone or Docetaxel for Castration-sensitive Metastatic Prostate Cancer? That Is the Question!

Carlo Messina1, Marco Messina2, Francesco Boccardo1

  • 1Academic Unit of Medical Oncology, Policlinico Hospital San Martino-IST, Genoa, Italy; Department of Internal Medicine, School of Medicine, University of Genoa, Genoa, Italy.

European Urology
|August 13, 2017
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.1K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

47.8K

Related Experiment Videos

Last Updated: Feb 24, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.9K
Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel
06:44

Generation of Prostate Cancer Cell Models of Resistance to the Anti-mitotic Agent Docetaxel

Published on: September 8, 2017

14.1K
Murine Prostate Micro-dissection and Surgical Castration
08:49

Murine Prostate Micro-dissection and Surgical Castration

Published on: May 11, 2016

47.8K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.0K

Articles linked to this work by shared authors, journal, and citation graph.

Molecular biomarkers in metastatic clear cell renal cell carcinoma treated with first-line immune combinations: a systematic review of phase III randomized clinical trials by Meet-URO group.

Cancer metastasis reviews·2026

Comparative Outcomes From 969 Endothelial Keratoplasties.

Cornea·2026

Patterns of first-line treatment selection in metastatic renal cell carcinoma: a real-world analysis from the Meet-URO 33-REGAL study.

Therapeutic advances in medical oncology·2026

Global Real-World Outcomes of Olaparib in Metastatic Castration-Resistant Prostate Cancer Patients With Homologous Recombination Repair Alterations.

International journal of cancer·2026

A National Survey Including Data from 5986 Dry Eyes Treated with a Novel Tear Substitute Containing Ribohyal.

Journal of clinical medicine·2026

Mismatch repair deficiency or microsatellite instability in locally advanced rectal cancer patients treated with total neoadjuvant therapy.

European journal of cancer (Oxford, England : 1990)·2026

Impact of Treatment Intensification with Abiraterone on Fracture-related Hospitalisation in Newly Diagnosed Prostate Cancer: A Secondary Analysis of Two Randomised Phase 3 Trials Within the STAMPEDE Trial Platform.

European urology·2026

Why Look Further When the Solution Is in Front of You - or Is It? The Value of Confirmatory PSA in Prostate Cancer Screening.

European urology·2026

Darolutamide Plus Androgen-deprivation Therapy in Metastatic Hormone-sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase 3 ARANOTE Trial.

European urology·2026

Hereditary Renal Cancer Syndromes: Redefining Clinical Management in the Era of Precision Medicine.

European urology·2026

PSMA Radio-guided Surgery to Identify Lymph Node Metastases in Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Phase 2 Prospective Study.

European urology·2026

Paclitaxel induces NM2-dependent cellular contraction through GEF-H1 dissociation from microtubules and RhoA/ROCK activation in cancer cells.

Molecular oncology·2026

Renal function and urinary tubular biomarker abnormalities in untreated and entecavir- or tenofovir disoproxil fumarate-treated patients with chronic hepatitis B: a retrospective cross-sectional study.

Frontiers in medicine·2026

A Latent profile and network intervention analysis of psychosomatic symptoms in lung cancer immunotherapy patients.

PloS one·2026

Cannabis Use by Veterans and Potential Interactions With Antineoplastic Agents: Analysis and Literature Review.

Federal practitioner : for the health care professionals of the VA, DoD, and PHS·2026

Combined treatment of benznidazole with an electrolyzed oxidizing water against Trypanosoma cruzi on immunological and anatomopathological features in a murine model of Chagas disease.

Frontiers in immunology·2026

Outcome of Ceftazidime/Avibactam Versus Alternative Antibiotics for Treatment of Carbapenem-Resistant Enterobacterales Bacteremia in Patients With Hematologic Malignancies.

Journal of Korean medical science·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us